Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA401 Targeting MAGEA4/8
Immatics’ first TCR Bispecific program IMA401 delivers preclinical proof-of-concept demonstrating complete remissions of…
Newsrooms
Immatics Appoints Biotech Executive Eliot Forster to Board of Directors
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and develop…
Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs
First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trial German regulatory agency, Paul-Ehrlic…
Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and develop…
Immatics Appoints Cedrik Britten as Chief Medical Officer
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T c…
Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapies
Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash h…
Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies
GSK to obtain access to two Immatics TCR-T programs, further advancing their commitment to the field of cell therapies I…
Immatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies
. Celgene Secures Exclusive Options to Three Immatics TCR-T Targets Immatics to Receive $75 Million Upfront Payment an…
Immatics Appoints Harpreet Singh as Chief Executive Officer
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-c…
Nature publication reports first-in-human trial for a personalized cancer immunotherapy
Clinical study demonstrates proof-of-concept for active personalized immunotherapy approach in a pioneering multi-center…